Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupFRA:MX6A +1.80%86 EV-to-FCF is 173.26 as of Jul. 17, 2026, which is 704% above its 10-year median of 21.56. GuruFocus rates FRA:MX6A with a GF Score™ of 86/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 564 Drug Manufacturers companies, Grand Pharmaceutical Group ranks worse than 91.31% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Grand Pharmaceutical Group's Enterprise Value is €2,402 Mil.
Grand Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €14 Mil. Therefore, Grand Pharmaceutical Group's EV-to-FCF for today is 173.26.
The historical rank and industry rank for Grand Pharmaceutical Group's EV-to-FCF or its related term are showing as below:
FRA:MX6A'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.6 Med: 21.56 Max: 381.2
Current: 161.46
During the past 13 years, the highest EV-to-FCF of Grand Pharmaceutical Group was 381.20. The lowest was 6.60. And the median was 21.56.
FRA:MX6A's EV-to-FCF is ranked worse than 91.31% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs FRA:MX6A: 161.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grand Pharmaceutical Group (FRA:MX6A) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grand Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Grand Pharmaceutical Group's share price for today is €0.565.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.039.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Grand Pharmaceutical Group EV-to-FCF Related Terms
Grand Pharmaceutical Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's EV-to-FCF falls into.
Grand Pharmaceutical Group's current Enterprise Value is €2,402 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) has a EV-to-FCF of 173.26 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grand Pharmaceutical Group and its competitors. This is 704% above median its historical median of 21.56. Over the past decade, Grand Pharmaceutical Group's EV-to-FCF has ranged from 6.60 to 381.20. According to the industry distribution chart, Grand Pharmaceutical Group ranks #515 out of 564 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Grand Pharmaceutical Group's EV-to-FCF too high?
Grand Pharmaceutical Group's current EV-to-FCF of 173.26 is 704% above median its 10-year median of 21.56. Over the past 10 years, this metric has ranged from a low of 6.60 to a high of 381.20. The Drug Manufacturers industry median EV-to-FCF is 20.82. Grand Pharmaceutical Group's value of 173.26 is 732.4% above this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #515 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #515 out of 564 companies for EV-to-FCF. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median EV-to-FCF is 20.82. Grand Pharmaceutical Group's value of 173.26 is 732.4% above this benchmark. Historically, Grand Pharmaceutical Group's own EV-to-FCF has ranged from 6.60 to 381.20 over the past decade. While the company's 10-year median is 21.56 vs. the industry median of 20.82, Grand Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current EV-to-FCF of 173.26 is 732.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current EV-to-FCF is 173.26, which is 704% above median its own 10-year median of 21.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.57 — trading 10.3% below its estimated fair value. The current EV-to-FCF is 173.26, which is 704% above median its 10-year median of 21.56 and 732.4% above the Drug Manufacturers industry median of 20.82. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current EV-to-FCF is 173.26 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
EV-to-FCF: 173.26 (704% above median its 10-year median of 21.56)
GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
Industry Position: 732.4% above the Drug Manufacturers median (#515 of 564)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score
Get the complete analysis for FRA:MX6A
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
